"Dihematoporphyrin Ether" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The purified component of HEMATOPORPHYRIN DERIVATIVE, it consists of a mixture of oligomeric porphyrins. It is used in photodynamic therapy (HEMATOPORPHYRIN PHOTORADIATION); to treat malignant lesions with visible light and experimentally as an antiviral agent. It is the first drug to be approved in the use of PHOTODYNAMIC THERAPY in the United States.
Descriptor ID |
D017323
|
MeSH Number(s) |
D03.383.129.578.840.500.462.400.200 D03.633.400.909.500.462.400.200 D04.345.783.500.462.400.200 D23.767.727.462.400.200
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Dihematoporphyrin Ether".
Below are MeSH descriptors whose meaning is more specific than "Dihematoporphyrin Ether".
This graph shows the total number of publications written about "Dihematoporphyrin Ether" by people in this website by year, and whether "Dihematoporphyrin Ether" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1999 | 1 | 0 | 1 |
2001 | 2 | 1 | 3 |
2003 | 1 | 1 | 2 |
2004 | 1 | 0 | 1 |
2006 | 2 | 0 | 2 |
2011 | 0 | 1 | 1 |
2012 | 1 | 0 | 1 |
2013 | 0 | 1 | 1 |
2015 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dihematoporphyrin Ether" by people in Profiles.
-
The effect of ephrin-A1 on resistance to Photofrin-mediated photodynamic therapy in esophageal squamous cell carcinoma cells. Lasers Med Sci. 2015 Dec; 30(9):2353-61.
-
Photodynamic therapy vs radiofrequency ablation for Barrett's dysplasia: efficacy, safety and cost-comparison. World J Gastroenterol. 2013 Nov 07; 19(41):7106-13.
-
The effects of Photofrin-mediated photodynamic therapy on the modulation of EGFR in esophageal squamous cell carcinoma cells. Lasers Med Sci. 2013 Feb; 28(2):605-14.
-
Photodynamic therapy. Gastrointest Endosc Clin N Am. 2011 Jan; 21(1):67-79.
-
Photofrin uptake in the tumor and normal tissues of patients receiving intraperitoneal photodynamic therapy. Clin Cancer Res. 2006 Sep 15; 12(18):5464-70.
-
A phase II trial of intraperitoneal photodynamic therapy for patients with peritoneal carcinomatosis and sarcomatosis. Clin Cancer Res. 2006 Apr 15; 12(8):2517-25.
-
Hypoxia and Photofrin uptake in the intraperitoneal carcinomatosis and sarcomatosis of photodynamic therapy patients. Clin Cancer Res. 2004 Jul 15; 10(14):4630-8.
-
Photodynamic therapy for sarcoma pulmonary metastases: a preclinical toxicity study. Anticancer Res. 2003 Sep-Oct; 23(5A):3713-8.
-
Correlation of in vivo photosensitizer fluorescence and photodynamic-therapy-induced depth of necrosis in a murine tumor model. J Biomed Opt. 2003 Apr; 8(2):248-52.
-
Vascularity and uptake of photosensitizer in small human tumor nodules: implications for intraperitoneal photodynamic therapy. Clin Cancer Res. 2001 Dec; 7(12):3904-11.